Novel frontiers in epilepsy treatments: Preventing epileptogenesis by targeting inflammation

Raimondo D'Ambrosio, Clifford L. Eastman, Cinzia Fattore, Emilio Perucca

Research output: Contribution to journalArticlepeer-review


Currently available epilepsy drugs only affect the symptoms (seizures), and there is a need for innovative treatments that target the underlying disease. Increasing evidence points to inflammation as a potentially important mechanism in epileptogenesis. In the last decade, a new generation of etiologically realistic syndrome-specific experimental models have been developed, which are expected to capture the epileptogenic mechanisms operating in corresponding patient populations, and to exhibit similar treatment responsiveness. Recently, an intervention known to have broad-ranging anti-inflammatory effects (selective brain cooling) has been found to prevent the development of spontaneously occurring seizures in an etiologically realistic rat model of post-traumatic epilepsy. Several drugs used clinically for other indications also have the potential for inhibiting inflammation, and should be investigated for antiepileptogenic activity in these models. If results of such studies are positive, these compounds could rapidly enter Phase III trials in patients at high risk of developing epilepsy.

Original languageEnglish
Pages (from-to)615-625
Number of pages11
JournalExpert Review of Neurotherapeutics
Issue number6
Publication statusPublished - Jun 2013


  • clinical trials
  • disease modification
  • drug treatment
  • epilepsy
  • epileptogenesis
  • experimental models
  • hypothermia
  • inflammation
  • traumatic brain injury

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)


Dive into the research topics of 'Novel frontiers in epilepsy treatments: Preventing epileptogenesis by targeting inflammation'. Together they form a unique fingerprint.

Cite this